Tilray Global

Medical Cannabis

Tilray is a global leader in medical cannabis research and production dedicated to providing safe, consistent and reliable therapy to patients. We are the first GMP-certified medical cannabis producer to supply cannabis flower and extract products to thousands of patients, physicians, pharmacies, hospitals, governments and researchers on four continents.

 
b-07.png

EXPERIENCE

Tilray's experience is unmatched worldwide. Our team of 130+ professionals on the ground in 5 countries serves thousands of patients around the globe. Our $26 million cultivation facility is among the most advanced in the world.

PRECISION

Tilray is the first GMP-certified medical cannabis producer to supply cannabis flower and extracts. All of our products are produced with meticulous care to ensure the highest quality, consistency and purity for our patients.

Lima01.jpg

RESEARCH

We are committed to scientific research that leads to an improved quality of life for patients in a time frame that matters. We are partnering with leading hospitals and universities to advance the clinical applications of cannabinoids.

x-06.png

CARE

Tilray takes tremendous pride in our customer service, patient outreach, and physician interaction. We recognize the importance of tracking potential adverse events as well as therapeutic benefits in order to ensure the safety of our patients.

 

Precisely formulated Products

Tilray cultivates a wide range of strains to meet patient needs including indicas, sativas, hybrids, and CBD-rich varieties. Tilray medical cannabis is available in two primary forms: extracts and dried flower. Each can be administered or consumed via a variety of methods. Tilray is working closely with patients, physicians, and regulators to provide consistent availability of a range of compliant and effective forms of medical cannabis.

 

Advancing Cannabinoid Science

For the therapeutic value and risks of cannabinoid-based medicines to be fully understood, Tilray believes it is critical to evolve current scientific understanding of the field. Our clinical research program is designed with that in mind. We understand the importance of developing well-characterized, consistent preparations of specific cannabinoid compositions that meet regulatory agencies’ standards for use in clinical research. We are actively supplying researchers around the world with cannabinoid products for clinical trials.

 

Facility Tour

 

Production Process

Tilray choreographs a complex series of cutting-edge processes spanning fourteen weeks to deliver an unparalleled medical cannabis product to its patients. From cultivation to final shipping, Tilray's team brings precision, professionalism and care to each stage of the process.

Locations

Our aspiration is to build the world’s most trusted and admired medical cannabis brand. As laws and regulations governing medical cannabis evolve in different jurisdictions, we are actively seeking to expand our operations to serve patients and researchers in need.

AUSTRALIA & NEW ZEALAND

In September 2016, Tilray became the first company to legally export medical cannabis products from North America to Australia for research and compassionate access purposes. In 2017, Tilray began shipping bulk imports to Australia under the country's new import regulations.  

CANADA
 

In 2014, Tilray began operating in Canada. Today, Tilray is the leading provider of high quality medical cannabis in the country, supplying thousands of patients in every province with consistent access to whole flower, milled blends and oils.

EUROPE


In June 2016, Tilray became the first company to legally export medical cannabis products from North America to Europe. In 2017, Tilray received a cultivation license from the Government of Portugal to produce products for the EU market. Tilray products are currently available at pharmacies in several EU countries.

LATIN
AMERICA

In February 2017, Tilray announced a strategic agreement  to distribute Tilray products in Chile and Brazil.

Management

Tilray's diverse management team of industry-leading experts includes PhD research scientists, master horticulturists, engineers, and patient advocates.

Medical Advisory Board

Orrin Devinsky, MD, Chairman . . .

Orrin Devinsky, MD, Chairman, is Director of the Comprehensive Epilepsy Center at the NYU Langone Medical Center. His research interests include the use of cannabinoids and other medications to treat a variety of epilepsy syndromes. He has served on the Board of Directors of the American Epilepsy Society, the Epilepsy Foundation and the Epilepsy Therapy Project, as well as the Scientific Advisory Boards of numerous disease organization. Dr. Devinsky has been an invited speaker at international epilepsy and neurology conferences for more than 20 years, and has authored over 400 peer-reviewed scientific articles and 20 books and monographs.

Praveen Anand, MD . . .

Praveen Anand, MD, is Head of the Centre for Clinical Translation and Professor of Clinical Neurology at Imperial College London. His research focuses on pathophysiological and molecular mechanisms in human sensory neuropathies and chronic pain syndromes. As Head of the Centre for Clinical Translation, he oversees the research and development of novel therapies for neurological diseases. Dr. Anand has worked extensively with pharmaceutical companies enabling translational research that has guided the recent success of three novel drugs from the laboratory to Phase II trials. He has published over 200 peer-reviewed articles in journals including Nature, Nature Medicine, Nature Genetics, Science and The Lancet.

Abraham Chachoua, MD . . .

Abraham Chachoua, MD, is Associate Director of Cancer Services at the NYU Langone Perlmutter Cancer Center and the Jay and Isabel Fine Professor of Oncology at the NYU Langone Department of Medicine. He specializes in the treatment of cancers that affect the lungs and chest. He has been involved in a number of clinical trials for the treatment of non-small cell lung cancer. Dr. Chachoua has a particular interest in the study of novel targeted therapies and earlier intervention in disease, integrating multiple modalities for the treatment of locally advanced lung cancer.

Elizabeth K. Hale, MD . . .

Elizabeth K. Hale, MD, is a Clinical Associate Professor of Dermatology at NYU Langone Medical Center and the co-Founder of CompleteSkinMD in New York City. She specializes in laser surgery and cosmetic dermatology. Dr. Hale has extensive experience in the field of skin cancer and is a senior vice president of the Skin Cancer Foundation. She has been named a “Best Doctor in Dermatology” by New York Magazine and a “Super Doctor” by the New York Times for the past five years. Dr. Hale has been an invited lecturer at international conferences focused on skin cancer and its treatment. Dr. Hale has authored over 40 peer-reviewed articles and more than 10 textbooks and chapters.

Catherine Lord, PhD . . .

Catherine Lord, PhD, is Professor of Psychology in Psychiatry and founding Director of the Center for Autism and the Developing Brain (CADB), a collaborative program between New York-Presbyterian Hospital, Weill Cornell Medicine, and Columbia University College of Physicians and Surgeons in partnership with New York Collaborates for Autism. She is internationally recognized for her work in longitudinal studies of children with autism as well as for her role in developing the autism diagnostic instruments used in both practice and in research worldwide today.

Tilray Updates

 

Press Coverage

Videos

// Move Video and Autoplay